Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial

Health Pharma & Biotech Edited by: Angela Harmantas 13:04 Mon 28 Sep 2026 --> Disclaimer No investment advice About this content Editorial Standards & Policies Share article About this content × About Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Use of technology Proactive has always been a forward looking and enthusiastic technology adopter. Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows. Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation. Kodiak Sciences Inc ( NASDAQ:KOD ) View Price & Profile Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial Published: 13:04 28 Sep 2026 EDT Kodiak Sciences Inc (NASDAQ:KOD) surged after Zenkuda and tabirafusp-ted met their primary endpoints in the phase III DAYBREAK trial for wet age-related macular degeneration. Shares gained over 162% by midday Monday following the announcement. Both experimental drugs demonstrated noninferiority to aflibercept in vision gains at one year, Kodiak said. Among Zenkuda patients, 54% reached 24-week dosing intervals at one year under strict criteria requiring retreatment when retinal fluid appeared. Zenkuda also matched or exceeded aflibercept's clinical effect during the initial loading phase, the company said. Tabirafusp-ted also met the trial's key secondary anatomical endpoint, alongside its primary vision endpoint. Kodiak said both experimental drugs demonstrated safety consistent with aflibercept's established safety profile. The results bring Zenkuda's total to five successful pivotal studies spanning wet AMD, diabetic retinopathy and macular edema following retinal vein occlusion. The company plans to submit Zenkuda's biologics license application in the fourth quarter of 2026, seeking approval across all three conditions. Continue reading